And so…we come to the most painful, controversial, and confusing of the definitions… ”intervention” and “interventional”.
Ideally, we would classify studies according to the level of intervention i.e., interventional, low intervention, and non-interventional. However, most regulators have been hesitant to define ‘intervention’ in their regulations. Only a few countries (e.g., USA, France, and South Africa) [refs 1 to 3] have defined “intervention” in the context of clinical trials.
If ‘intervention’ isn’t defined in the regulations of the region of interest it becomes difficult (impossible) to define what is, and is not, an intervention, and therefore what is, and is not, a clinical trial.
There is a simple solution. Most countries define a ‘clinical trial’.
For example, in Europe: ‘Clinical trial’ means a clinical study which fulfils any of the following conditions [ref 4]:
(a) the assignment of the subject to a particular therapeutic strategy is decided in advance and does not fall within normal clinical practice of the Member State concerned;
(b) the decision to prescribe the investigational medicinal products is taken together with the decision to include the subject in the clinical study; or
(c) diagnostic or monitoring procedures in addition to normal clinical practice are applied to the subjects
So…when classifying a clinical study, the recommendation is to determine whether the proposed study is a clinical trial.
If the study isn’t a clinical trial, then what is it?
In Europe, a ‘non-interventional study’ is a clinical study other than a clinical trial [ref 4].
Therefore, in Europe both clinical trials and non-interventional studies (NIS) are investigations in humans that involves a medicinal product. Whereas, clinical trials involve protocol-defined healthcare interventions, and NIS do not.
References:
[1] Section III.A of the FDA Guidance – Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products (August 2023): https://www.fda.gov/media/171667/download
[2] Article L1121-1 of the Public Health Code (CSP): https://www.legifrance.gouv.fr/codes/article_lc/LEGIARTI000032722870/
[3] Glossary of the Department of Health – Ethics in Health Research Guidelines: Principles, Processes and Structures (2015): https://www.health.gov.za/wp-content/uploads/2022/05/NHREC-DoH-2015-Ethics-in-Health-Research-Guidelines-1.pdf
[4] Article 2 of the EU Clinical Trials Regulation (Regulation EU/536/2014): https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02014R0536-20221205
In essence, definitions lay the groundwork for accurate, consistent, and meaningful research, especially in areas where the data and its sources are as diverse and complex as in RWD and RWE.
Share this story...
Denmark – A Hub for RWE Research
RWE 201 - Denmark – A Hub for RWE Research Denmark has been at the forefront of real-world data (RWD) and real-world evidence (RWE) initiatives in the realm of [...]
NORWAIT – A Cautionary Tale
RWE 201 - NORWAIT – A Cautionary Tale Norwait Study: https://rwr-regs.com/norway-norwait-study-deterioration-for-several-participants-in-a-controversial-observational-cancer-study/Observational studies, as the term implies, typically involve low to no risk for patients. Their main purpose is to [...]
Norway – Real World Data Initiatives
RWE 201 - Norway – Real World Data Initiatives Norway has made significant strides in real-world data (RWD) and real-world evidence (RWE) initiatives, particularly within the healthcare [...]
Sweden – Pioneering the Use of RWD
RWE 201 - Sweden – Pioneering the Use of RWD Cancer Registry: https://www.socialstyrelsen.se/statistik-och-data/register/cancerregistret/Sweden has been a pioneer in several real-world data (RWD) and real-world evidence (RWE) initiatives, particularly in [...]
Finland – Leaders in Integrating RWE into Healthcare, Policy, and Research
RWE 201 - Finland – Leaders in Integrating RWE into Healthcare, Policy, and Research Finland – Secondary Use of Health Data: https://stm.fi/en/secondary-use-of-health-and-social-dataFinland has been a frontrunner in the utilization [...]
Italy – CCNCE – Ethical and Regulatory Issues in the Processing of Patient Data in Observational Research
RWE 201 - Italy – CCNCE – Ethical and Regulatory Issues in the Processing of Patient Data in Observational Research CCNCE Reflection Paper (Apr 2023): https://www.aifa.gov.it/documents/20142/1808580/Criticita_etiche_ricerca_osservazionale_06.04.2023.pdfThe Italian National Coordination [...]







